CDKN2A and neoplasm: Whole-exome VSCC data further delineate recurrent alterations, including TP53 (67%), FAT1 (28%), CDKN2A (25%), RNF213 (23%), NFE2L2 (20%) and PIK3CA (20%), with CCND1 copy-number gains in 28% and universal MMR proficiency; TP53 mutation, CCND1 gain, and their combination are associated with poorer recurrence-free and disease-specific survival, and every tumor harbored at least one potentially actionable alteration [97,98].